<div id="readability-page-1"><p>LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Dyne Therapeutics today and set a price target of $44.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Brisebois is a 3-star analyst with an average return of <span>2.4%</span> and a 40.11% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics.</p> <p>In addition to LifeSci Capital, Dyne Therapeutics also received a Buy from Evercore ISI’s Gavin Clark-Gartner in a report issued yesterday. However, on May 13, Bernstein assigned a Hold rating to Dyne Therapeutics (NASDAQ: DYN).</p></div>

ARKG

LABU

<p>LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $44.00. Brisebois, a 3-star analyst, has an average return of 2.4% and a 40.11% success rate. Dyne Therapeutics also received a Buy rating from Evercore ISI, while Bernstein assigned a Hold rating on May 13.</p>

Tip Ranks

Dyne Therapeutics

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Savara

Praxis Precision Medicines

Opus Genetics

Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital